News Ionis hit by safety concerns, rivals Alnylam benefit Biotech insists drug for rare inherited disorder is still approvable.
Cancer AZ confirms move to acquire cancer specialist Acerta Acerta brings with it a promising lead candidate
News RNAi biotech City hauls in $200m in upsized IPO City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
